Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
28201 | 173 | 34.2 | 83% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
3389 | 1184 | KIKUCHI FUJIMOTO DISEASE//HISTIOCYTIC NECROTIZING LYMPHADENITIS//RCAS1 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | RCAS1 | Author keyword | 220 | 95% | 43% | 74 |
2 | EBAG9 | Author keyword | 17 | 100% | 5% | 8 |
3 | RECEPTOR BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS | Author keyword | 6 | 100% | 2% | 4 |
4 | GYNECOL INFERTIL | Address | 5 | 45% | 5% | 9 |
5 | OUTPATIENT UNIT OTOLARYNGOL | Address | 4 | 75% | 2% | 3 |
6 | GYNECOL OBSTET ONCOL | Address | 4 | 35% | 5% | 9 |
7 | RCAS1 ANTIGEN | Author keyword | 3 | 100% | 2% | 3 |
8 | RECEPTOR BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS RCAS1 | Author keyword | 3 | 100% | 2% | 3 |
9 | SRCAS1 | Author keyword | 3 | 100% | 2% | 3 |
10 | CHAIR GYNECOL ONCOL GYNECOL NURSING | Address | 3 | 45% | 3% | 5 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | RCAS1 | 220 | 95% | 43% | 74 | Search RCAS1 | Search RCAS1 |
2 | EBAG9 | 17 | 100% | 5% | 8 | Search EBAG9 | Search EBAG9 |
3 | RECEPTOR BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS | 6 | 100% | 2% | 4 | Search RECEPTOR+BINDING+CANCER+ANTIGEN+EXPRESSED+ON+SISO+CELLS | Search RECEPTOR+BINDING+CANCER+ANTIGEN+EXPRESSED+ON+SISO+CELLS |
4 | RCAS1 ANTIGEN | 3 | 100% | 2% | 3 | Search RCAS1+ANTIGEN | Search RCAS1+ANTIGEN |
5 | RECEPTOR BINDING CANCER ANTIGEN EXPRESSED ON SISO CELLS RCAS1 | 3 | 100% | 2% | 3 | Search RECEPTOR+BINDING+CANCER+ANTIGEN+EXPRESSED+ON+SISO+CELLS+RCAS1 | Search RECEPTOR+BINDING+CANCER+ANTIGEN+EXPRESSED+ON+SISO+CELLS+RCAS1 |
6 | SRCAS1 | 3 | 100% | 2% | 3 | Search SRCAS1 | Search SRCAS1 |
7 | B7H4 | 1 | 50% | 1% | 2 | Search B7H4 | Search B7H4 |
8 | EBAG9 RCAS1 | 1 | 100% | 1% | 2 | Search EBAG9+RCAS1 | Search EBAG9+RCAS1 |
9 | MATERNAL IMMUNE TOLERANCE | 1 | 100% | 1% | 2 | Search MATERNAL+IMMUNE+TOLERANCE | Search MATERNAL+IMMUNE+TOLERANCE |
10 | OXYTOCINASE | 1 | 12% | 3% | 6 | Search OXYTOCINASE | Search OXYTOCINASE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTIGEN RCAS1 | 74 | 81% | 25% | 44 |
2 | EBAG9 RCAS1 EXPRESSION | 33 | 100% | 8% | 13 |
3 | HUMAN UTERINE | 28 | 69% | 14% | 24 |
4 | SISO CELLS | 27 | 92% | 6% | 11 |
5 | RCAS1 EXPRESSION | 15 | 82% | 5% | 9 |
6 | RCAS1 | 12 | 63% | 7% | 12 |
7 | EBAG9 RCAS1 | 12 | 86% | 3% | 6 |
8 | ANTIGEN 22 1 1 EXPRESSION | 8 | 100% | 3% | 5 |
9 | EBAG9 GENE | 8 | 100% | 3% | 5 |
10 | SISO CELLS RCAS1 | 6 | 100% | 2% | 4 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Receptor-binding cancer antigen expressed on SiSo cells (RCAS1): a novel biomarker in the diagnosis and prognosis of human neoplasia | 2009 | 13 | 74 | 88% |
RCAS1, MT, and Vimentin as Potential Markers of Tumor Microenvironment Remodeling | 2010 | 20 | 39 | 36% |
Novel therapeutic strategies to target RCAS1, which induces apoptosis via ectodomain shedding | 2011 | 4 | 95 | 56% |
Significance of RCAS1 antigen in hepatocellular, cholangiocenular and pancreatic carcinomas | 2005 | 15 | 40 | 93% |
Biology of cancer: Thermodynamic answers to some questions | 2001 | 13 | 1 | 100% |
Immunotherapy of cervical cancer as a biological dissipative structure | 2011 | 1 | 8 | 50% |
Historic discovery of natural thermodynamic cause of cancer | 2012 | 0 | 19 | 68% |
Obstetrical prevention of human cancers | 2012 | 0 | 9 | 44% |
Cancer therapy using tumor-associated antigens to reduce side effects | 2009 | 6 | 108 | 22% |
Technology based on expression microarrays, proteomic microarrays and tissue microarrays in mammalian oncogenesis research | 2011 | 1 | 30 | 27% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GYNECOL INFERTIL | 5 | 45% | 5.2% | 9 |
2 | OUTPATIENT UNIT OTOLARYNGOL | 4 | 75% | 1.7% | 3 |
3 | GYNECOL OBSTET ONCOL | 4 | 35% | 5.2% | 9 |
4 | CHAIR GYNECOL ONCOL GYNECOL NURSING | 3 | 45% | 2.9% | 5 |
5 | UNIT IMMUNE SURVEILLANCE | 2 | 36% | 2.3% | 4 |
6 | LUKASZCZYK ONCOL BYDGOSZCZ | 1 | 50% | 1.2% | 2 |
7 | MED ENVIRONM PREGNANCY HLTH HAZARDS UNIT | 1 | 30% | 1.7% | 3 |
8 | CHAIR GYNECOL OBSTET 1 | 1 | 25% | 1.7% | 3 |
9 | TUMOR PATHOL PATHOMORPHOL | 1 | 17% | 2.3% | 4 |
10 | GYNAECOL INFERTIL | 1 | 50% | 0.6% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000092723 | AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY//DECIDUA//PROGESTERONE INDUCED BLOCKING FACTOR |
2 | 0.0000065921 | CHRONIC ENDOMETRITIS//BIOMED HUMAN ONCOL SCI DIMO//ENDOMETRIAL MICROPOLYPS |
3 | 0.0000048392 | CA 19 9//CA19 9//SPAN 1 |
4 | 0.0000047787 | AGAR SOLUTIONS//RADIOL SCI TECHNOL//BIAG |
5 | 0.0000045939 | FAS//FAS LIGAND//AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME |
6 | 0.0000041339 | CD3 ZETA//ORAL BIOL ORAL MED//ZETA CHAIN |
7 | 0.0000038130 | HLA G//SOLUBLE HLA G//SERV RECH HEMATOIMMUNOL |
8 | 0.0000036711 | FETAL MACROPHAGES//TERMINAL VILLI//FIBRINOID |
9 | 0.0000033618 | CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE |
10 | 0.0000031161 | MOTHERS BABIES//SIR QUINTON HAZELL MOL MED//OVARIAN CRH |